---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-002533"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2022-11-30T23:59:59+00:00"
generated_at: "2026-06-21T11:34:31.185095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience: DehydraTECH-CBD shows better seizure control at lower doses vs. Epidiolex in animal study

## Summary
- Pilot study: at 50 mg/kg, only DehydraTECH-CBD showed seizure reduction; at 75 mg/kg, full elimination in 66.6% of animals vs. 50% for Epidiolex.
- Time to peak efficacy: at 30 min, 50% of DehydraTECH-CBD animals had partial/full seizure elimination vs. 0% for Epidiolex; at 60 min, 87.5% vs. 62.5%.
- ED50 study (dose for 50% seizure inhibition) is underway; results will be reported separately.
- Study EPIL-A21-1 uses MES model in rats; fully funded by Lexaria and performed by a US independent lab.

## SEC filing metadata
- accession: 0001640334-22-002533
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2022-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033422002533/0001640334-22-002533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033422002533/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-002533
- JSON: https://secwatch.observer/filing/0001640334-22-002533.json
- Plain text: https://secwatch.observer/filing/0001640334-22-002533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.